10-Q: MEDO Technologies Reports Q3 2026 Results, Faces Going Concern Doubt

MEDO Technologies, Inc. filed its Q3 2026 Form 10-Q, revealing significant operating losses and a precarious financial position that raises substantial doubt about its ability to continue as a going concern.

Summary

• MEDO Technologies, Inc. (formerly Bryn Inc.) filed its quarterly report for the period ending September 30, 2026.
• The company reported a net loss of $191,301 for the three months ended September 30, 2026, and $400,884 for the nine months ended September 30, 2026.
• As of September 30, 2026, the company had a working capital deficit of $395,562 and an accumulated deficit of $117,963,021.
• Management acknowledges substantial doubt about the company's ability to continue as a going concern, dependent on obtaining additional financing and achieving profitable operations.
• The company completed a 1-for-100,000 reverse stock split effective September 23, 2026.
• The company's business plan involves acquiring pharmaceutical distributors and optimizing them with AI-based technology.
• There are material weaknesses in internal controls, including insufficient segregation of duties and lack of an independent board or audit committee.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a very negative filing due to significant operating losses, a substantial working capital deficit, and explicit statements raising substantial doubt about the company's ability to continue as a going concern.

Positives

• The company has a stated business plan to acquire pharmaceutical distributors and implement AI-based optimization.
• Related party loans from Medo Healthcare, LLC are interest-free.
• The company has filed all required reports.
• The company has a new name, MEDO Technologies, Inc., reflecting its planned business direction.

Negatives

• Significant operating losses continue, with a net loss of $191,301 for Q3 2026 and $400,884 for the nine months ended September 30, 2026.
• A substantial working capital deficit of $395,562 and an accumulated deficit of $117,963,021 as of September 30, 2026.
• Management explicitly states substantial doubt about the company's ability to continue as a going concern.
• The company has no revenue from operations as of the report date.
• Material weaknesses in internal controls are identified, including lack of segregation of duties, no independent board or audit committee, and lack of written policies.
• The company's common stock is very thinly traded.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing, generating sufficient revenues, and achieving profitable operations.
• Additional financing may not be available upon acceptable terms, or at all.
• The company may be required to issue a controlling block of securities to acquire targets, leading to dilution for current shareholders.
• The company anticipates incurring operating losses in the next 12 months, primarily related to SEC reporting obligations.
• Risks include an evolving and unpredictable business model, challenges in revenue recognition, and management of growth.
• The continued availability of financial support from Medo Healthcare, LLC is not guaranteed.

Future Outlook

The company anticipates incurring operating losses in the next 12 months, primarily related to SEC reporting obligations. Its future operations are contingent on securing additional financing, potentially through debt and equity, and achieving profitable operations. The business plan involves acquiring pharmaceutical distributors and optimizing them with AI-based technology, which may require significant capital and could lead to dilution for current shareholders.

Management Comments

• Management acknowledges that the company has no operations from a continuing business other than expenditures related to running the company and has no revenue from operations as of the date of this Report.
• Management states that based upon current operations, the company does not have sufficient working capital to fund operations over the next 12 months.
• Management believes that if acquisitions are closed, capital will likely be needed as a condition of closing those acquisitions.
• Management notes that additional issuances of equity or convertible debt securities will result in dilution to current shareholders and such securities might have rights, preferences, or privileges senior to Common Stock.
• Management states that if adequate funds are not available or are not available on acceptable terms, the company may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict business operations.
• Management plans to rectify material weaknesses in internal controls by implementing an independent board of directors, establishing written policies and procedures, and hiring additional accounting personnel after completing a reverse merger or similar business acquisition.

Industry Context

StockSavvy.ai notes that MEDO Technologies is positioning itself within the pharmaceutical distribution sector, aiming to leverage AI for optimization. This aligns with a broader industry trend of technology adoption to improve efficiency and reduce costs in healthcare supply chains. However, the company's current lack of revenue and significant financial distress place it in a highly speculative position within this evolving landscape.

Comparison to Industry Standards

• As a smaller reporting company with no current revenue and significant going concern issues, direct comparison to established pharmaceutical distributors like McKesson, Cardinal Health, or AmerisourceBergen is not meaningful. These companies operate at scale with substantial revenues, profitability, and established market positions.
• The company's stated reliance on AI for optimization is a nascent strategy. While AI adoption is growing across the healthcare and logistics sectors, its successful implementation and impact on profitability for a company in MEDO's financial state remain unproven.
• The significant operating losses and negative working capital are far outside the norms for healthy companies in the pharmaceutical distribution industry, which typically exhibit positive cash flows and robust balance sheets.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not aware of any threatened or pending litigation that would have a material adverse effect.

Related Party Transactions

• During the nine months ended September 30, 2026, David Lazar and Medo Healthcare, LLC extended $12,900 and $321,874 respectively, in interest-free demand loans.
• During the three months ended March 31, 2026, Mr. Lazar received 300 common shares in exchange for cancelling $93,285 of debt, valued at approximately $0.003 per share (pre-split).
• Mr. Lazar forgave an additional $8,649 of debt during the three months ended June 30, 2026.
• As of September 30, 2026, the balance of related party loans was $321,874, solely due to Medo Healthcare, LLC.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to anticipated future equity or convertible debt issuances. The company's going concern status poses a high risk to existing investments.
• Creditors: The company's financial condition and going concern issues may impact its ability to repay debts.
• Management/Employees: The company's survival and future growth depend heavily on securing financing and executing its business plan, creating an uncertain operating environment.

Next Steps

• Acquire pharmaceutical distributors with a nation-wide scope.
• Implement proprietary AI-based technology to optimize acquired businesses.
• Seek additional debt and equity financing to fund operations and potential acquisitions.
• Address material weaknesses in internal controls by implementing an independent board, written policies, and hiring additional accounting personnel.

Key Dates

Recommendation

The filing indicates severe financial distress, with substantial doubt about the company's ability to continue as a going concern, no current revenue, significant operating losses, and material weaknesses in internal controls. While there is a stated business plan, its execution is contingent on substantial future financing that is not guaranteed, and any such financing is likely to be highly dilutive. The current financial state and outlook present an unacceptably high risk for investors.

Keywords

MEDO Technologies, Quarterly Report, Form 10-Q, Financial Statements, Going Concern, Operating Loss, Reverse Stock Split, Pharmaceutical Distributors